190 related articles for article (PubMed ID: 37385631)
1. Anakinra versus etoposide-based therapy added to high-dose steroids for the treatment of secondary hemophagocytic lymphohistiocytosis.
Lee BJ; Cao Y; Vittayawacharin P; É'Leima G; Rezk S; Reid J; Brem EA; Ciurea SO; Kongtim P
Eur J Haematol; 2023 Sep; 111(3):477-484. PubMed ID: 37385631
[TBL] [Abstract][Full Text] [Related]
2. The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis.
Bami S; Vagrecha A; Soberman D; Badawi M; Cannone D; Lipton JM; Cron RQ; Levy CF
Pediatr Blood Cancer; 2020 Nov; 67(11):e28581. PubMed ID: 32725881
[TBL] [Abstract][Full Text] [Related]
3. Interleukin 1 Receptor Antagonist Anakinra, Intravenous Immunoglobulin, and Corticosteroids in the Management of Critically Ill Adult Patients With Hemophagocytic Lymphohistiocytosis.
Wohlfarth P; Agis H; Gualdoni GA; Weber J; Staudinger T; Schellongowski P; Robak O
J Intensive Care Med; 2019 Sep; 34(9):723-731. PubMed ID: 28631531
[TBL] [Abstract][Full Text] [Related]
4. Anakinra for the treatment of adult secondary HLH: a retrospective experience.
Naymagon L
Int J Hematol; 2022 Dec; 116(6):947-955. PubMed ID: 35948764
[TBL] [Abstract][Full Text] [Related]
5. Experience with hemophagocytic lymphohistiocytosis/macrophage activation syndrome at a single institution.
Gupta AA; Tyrrell P; Valani R; Benseler S; Abdelhaleem M; Weitzman S
J Pediatr Hematol Oncol; 2009 Feb; 31(2):81-4. PubMed ID: 19194188
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically ill children*.
Rajasekaran S; Kruse K; Kovey K; Davis AT; Hassan NE; Ndika AN; Zuiderveen S; Birmingham J
Pediatr Crit Care Med; 2014 Jun; 15(5):401-8. PubMed ID: 24583503
[TBL] [Abstract][Full Text] [Related]
7. The Efficacy of Etoposide-Based Therapy in Adult Secondary Hemophagocytic Lymphohistiocytosis.
Naymagon L; Tremblay D; Mascarenhas J
Acta Haematol; 2021; 144(5):560-568. PubMed ID: 33827086
[TBL] [Abstract][Full Text] [Related]
8. Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis/macrophage activation syndrome: A systematic review.
Charlesworth JEG; Kavirayani A
Eur J Haematol; 2023 Sep; 111(3):458-476. PubMed ID: 37344166
[TBL] [Abstract][Full Text] [Related]
9. [Report of a case with secondary acute promyelocytic leukemia after therapy for hemophagocytic lymphohistiocytosis and review of literature].
Su Y; Zhou X; Zhang L; Zhang R
Zhonghua Er Ke Za Zhi; 2013 Dec; 51(12):938-42. PubMed ID: 24495767
[TBL] [Abstract][Full Text] [Related]
10. [Diagnostics and treatment of hemophagocytic lymphohistiocytosis].
Eichenauer DA; Böll B
Inn Med (Heidelb); 2023 Nov; 64(11):1077-1084. PubMed ID: 37855882
[TBL] [Abstract][Full Text] [Related]
11. Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis.
Eloseily EM; Weiser P; Crayne CB; Haines H; Mannion ML; Stoll ML; Beukelman T; Atkinson TP; Cron RQ
Arthritis Rheumatol; 2020 Feb; 72(2):326-334. PubMed ID: 31513353
[TBL] [Abstract][Full Text] [Related]
12. Systemic and Nodular Hyperinflammation in a Patient with Refractory Familial Hemophagocytic Lymphohistiocytosis 2.
Segal JE; Daley JD; Barnum JL; Salgado CM; Reyes-Mugica M; Schneider C; Gumus S; Thakrar D; Allen SW; Canna SW
J Clin Immunol; 2021 Jul; 41(5):987-991. PubMed ID: 33570715
[TBL] [Abstract][Full Text] [Related]
13. Successful use of subcutaneous anakinra in hemophagocytic lymphohistiocytosis precipitated by candidiasis in a patient with systemic lupus erythematosus: A case report and description of a novel therapeutic regimen.
Xu G; Islam ST; Makarie-Rofail L; Barnsley L; Limaye S
Int J Rheum Dis; 2023 Nov; 26(11):2284-2287. PubMed ID: 37150523
[TBL] [Abstract][Full Text] [Related]
14. Hemophagocytic lymphohistiocytosis after SARS-CoV-2 vaccination.
Hieber ML; Sprute R; Eichenauer DA; Hallek M; Jachimowicz RD
Infection; 2022 Oct; 50(5):1399-1404. PubMed ID: 35218512
[TBL] [Abstract][Full Text] [Related]
15. Acute myeloid leukemia following etoposide therapy for EBV-associated hemophagocytic lymphohistiocytosis: a case report and a brief review of the literature.
Pan H; Feng DN; Song L; Sun LR
BMC Pediatr; 2016 Jul; 16():116. PubMed ID: 27473573
[TBL] [Abstract][Full Text] [Related]
16. A Review of Current and Emerging Therapeutic Options for Hemophagocytic Lymphohistiocytosis.
Summerlin J; Wells DA; Anderson MK; Halford Z
Ann Pharmacother; 2023 Jul; 57(7):867-879. PubMed ID: 36349896
[TBL] [Abstract][Full Text] [Related]
17. Diagnosing and treating hemophagocytic lymphohistiocytosis in the tropics: systematic review from the Indian subcontinent.
Rajagopala S; Singh N
Acta Med Acad; 2012; 41(2):161-74. PubMed ID: 23331391
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis.
Bubik RJ; Barth DM; Hook C; Wolf RC; Muth JM; Mara K; Patnaik MS; Pruthi RK; Marshall AL; Litzow MR; Elliott MA; Hogan WJ; Shah MV; Begna KH; Alkhateeb H; Pardanani A; Ashrani AA; Call TG; Rivera CE; Camoriano JK; Go RS; Wolanskyj-Spinner AP; Parikh SA
Leuk Lymphoma; 2020 Jul; 61(7):1592-1600. PubMed ID: 32157935
[TBL] [Abstract][Full Text] [Related]
19. Practice patterns and outcomes of hemophagocytic lymphohistiocytosis in adults: a 2-decade provincial retrospective review.
Croden J; Bilston L; Taparia M; Grossman J; Sun HL
Ann Hematol; 2022 Oct; 101(10):2297-2306. PubMed ID: 35978181
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of mycobacterial infection associated hemophagocytic lymphohistiocytosis with etoposide and anti-tuberculous therapy: a case report.
Wang YH; Ba JH; Shi XW; Wu BQ
BMC Infect Dis; 2020 May; 20(1):321. PubMed ID: 32370734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
